Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid Stoffw Microb

Hatzl, S; Posch, F; Rezai, A; Gornicec, M; Beham-Schmid, C; Magnes, T; Wangner, S; Deutsch, A; Greinix, H; Uhl, B; Prochazka, KT; Egle, A; Greil, R; Melchardt, T; Linkesch, W; Schulz, E; Neumeister, P.
Vinorelbine as substitute for vincristine in patients with diffuse large B cell lymphoma and vincristine-induced neuropathy.
Support Care Cancer. 2021; 29(9):5197-5207 Doi: 10.1007/s00520-021-06059-2 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG


Führende Autor*innen der Med Uni Graz
Hatzl Stefan
Neumeister Peter
Co-Autor*innen der Med Uni Graz
Beham-Schmid Christine
Deutsch Alexander
Greinix Hildegard
Linkesch Werner
Posch Florian
Prochazka Katharina
Schulz Eduard
Uhl Barbara

Dimensions Citations:

Plum Analytics:

Scite (citation analytics):

BACKGROUND: A combination of rituximab with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) is the standard first-line therapy for diffuse large B cell lymphoma (DLBCL), the most common aggressive lymphoma in adults. One of the major adverse effects of this regimen is vincristine-induced polyneuropathy which leads to discontinuation of vincristine in up to 30% of DLBCL-patients. Dose reduction of vincristine might worsen treatment outcomes of DLBCL but identification of treatment alternatives for patients exhibiting peripheral neuropathy during R-CHOP is an unmet need in hematology. METHODS: In this retrospective cohort study, comprising 987 patients with de novo DLBCL, we delineated the role of vinorelbine as a substitute for vincristine in R-CHOP by measuring improvements in neuropathy and outcome variables. RESULTS: Five-year overall survival (OS) and progression-free survival (PFS) were 72.6% and 63.1% in patients who received regular doses of vincristine, as compared to 60.6% and 51.7% in patients who received reduced doses of vincristine (p = 0.022 and p = 0.003, respectively). Of 199 patients who switched to vinorelbine, the majority experienced an improvement of neuropathy Furthermore, vinorelbine-switched patients showed favorable oncologic outcomes. CONCLUSION: Replacement of vincristine by vinorelbine due to neuropathy is effective and safe, and results in a significant improvement in neuropathy as compared to treatment with R-CHOP.
Find related publications in this database (using NLM MeSH Indexing)
Aged - administration & dosage
Antineoplastic Combined Chemotherapy Protocols - adverse effects
Cyclophosphamide - adverse effects
Doxorubicin - adverse effects
Female - administration & dosage
Hematopoietic Stem Cell Transplantation - administration & dosage
Humans - administration & dosage
Lymphoma, Large B-Cell, Diffuse - drug therapy
Male - administration & dosage
Middle Aged - administration & dosage
Peripheral Nervous System Diseases - chemically induced, epidemiology
Prednisone - adverse effects
Retrospective Studies - administration & dosage
Rituximab - adverse effects
Transplantation, Autologous - administration & dosage
Vincristine - adverse effects
Vinorelbine - administration & dosage

Find related publications in this database (Keywords)
Peripheral neuropathy
© Med Uni Graz Impressum